| SHZAMSTOCKS' FEATURED PROFILES |
|
| FREE
STOCK PICKS IN YOUR EMAIL |
|
|
PROFILES
Welcome to our comprehensive profile on Imagin Molecular Corporation
(OTCBB: IMGM)
|
BUSINESS DEVELOPMENT
Through its wholly-owned subsidiary, Imagin Nuclear Partners Corporation, the Company utilizes Positron Emission Tomography myocardial perfusion imaging technology ("PET" or "PET imaging technology") and related technical and educational services to diagnose and treat patients with coronary artery disease and patients who are at risk of developing coronary heart disease. The Company will attempt to establish heart health centers to provide imaging technology for the diagnosis and non-invasive management of coronary artery disease. The Company plans to use PET perfusion imaging and vigorous risk factor modification programs to diagnose and guide the management of patients with coronary artery disease. This program is aimed at the regression of coronary atherosclerosis and stabilization of plaque to prevent the clinical events of myocardial infarction, sudden death and unstable coronary syndromes requiring invasive intervention (PTCA or bypass surgery).
The Company's methodology differs than that of traditional invasive coronary procedures by health care providers that has not resulted in significant improvement in clinical outcomes for coronary patients, primarily due to what the Company perceives as limitations of the imaging technology currently employed by health care providers and the failure to focus on lifestyle modification programs for coronary patients. The Company believes that the current barriers to entry of Positron Emission Tomography Myocardial Perfusion Imaging (PET MPI) have prevented widespread utilization.
Studies have shown that the utilization of PET imaging technology is a cost-effective approach to the diagnosis of coronary artery disease when compared to the cost of utilizing traditional imaging technology and invasive procedures. The current approximate cost of a PET scanner, in excess of $1,500,000 continues to prevent wide spread acceptance of the technology. The Company believes that if the technology could be offered at prices equivalent to the less accurate, less expensive, routinely used, diagnostic exam of Single Photon Emission Computed Tomography (SPECT) that the barriers to entry will be significantly reduced leading to an increased utilization.
The Company intends to establish regional heart health centers throughout North America as freestanding outpatient facilities that will provide the most advanced imaging technology for the diagnosis and non-invasive management of coronary artery disease. An outstanding physician, nursing and technical staff will deliver this unsurpassed level of care. The Company's key strengths are operational expertise in state-of the art cardiovascular PET imaging technology, effective clinical algorithms for coronary artery disease regression and an experienced management team.
The Company's operational expertise is based on the pioneering work of renowned cardiologist Dr. K. Lance Gould and Dr. Michael E. Merhige on coronary artery disease reversal and prevention through aggressive noninvasive medical management guided objectively in each individual patient by PET. When PET guided results were compared to conventional management using Single Photon Emission Computed Tomography (SPECT), the experience resulted in a 50% reduction in the utilization of angiography and bypass surgery with an associated 25% reduction in treatment costs. Patient outcome analysis demonstrated a 50% reduction in cardiac mortality and a 50% reduction in myocardial infarction or heart attack.(4) This represents a "win-win-win", for patients, practitioners and health care payers, through decreased utilization of the invasive management of coronary artery disease (CABG and angiography). |
|
